Cromos Pharma, where the patients are

Illumina

Illumina launches the Illumina Accelerator Program

Friday, February 14, 2014 01:52 PM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has launched the Illumina Accelerator Program, the world's first business accelerator focused solely on creating an innovation ecosystem for the genomics industry. Its goal is to speed the time to market and lower the barriers to entry for entrepreneurs, startups and early stage companies working on scientifically and commercially promising next-generation sequencing (NGS) applications.

More... »

CRF Health eCOA webinar series

Sony, M3, Illumina to launch new genome company in Japan

Monday, January 27, 2014 01:24 PM

Sony, M3 and Illumina have formed a collaboration to launch a "genome information platform" in Japan. Sony and M3 will establish a new company, with Illumina as a minority investor, by the end of February.

More... »


Amgen, Illumina to develop oncology companion diagnostic test

Friday, January 17, 2014 11:42 AM

Illumina, a developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function, has entered into an agreement with Amgen to develop and commercialize a multigene, NGS-based test as a companion diagnostic for Vectibix (panitumumab), a fully human anti-EGFR monoclonal antibody therapeutic for the treatment of metastatic colorectal cancer approved in the U.S. and E.U.

More... »

Illumina to acquire NextBio

Monday, October 28, 2013 02:20 PM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function based in San Diego, will acquire Santa Clara-based NextBio, a provider of clinical and genomic informatics.

More... »

University of Cambridge, Genomics England, Illumina collaborate

Monday, October 21, 2013 01:36 PM

University of Cambridge, Genomics England and Illumina have announced the launch of a three-year project to sequence 10,000 whole genomes of children and adults with rare genetic diseases. The project is a pilot for Genomics England, which will provide 2,000 samples, and marks the beginning of the national endeavor to sequence 100,000 genomes in the U.K. National Health Service (NHS).

More... »

Almac launches TruSight tumor profiling next-generation sequencing service

Wednesday, September 11, 2013 01:37 PM

Almac has launched a tumor profiling service running Illumina’s next-generation sequencing (NGS) TruSight Tumor panel as part of their biomarker discovery, development and delivery solutions.

More... »

Pathogenica, Illumina in co-marketing deal

Wednesday, July 17, 2013 12:30 PM

Pathogenica, a provider of medical diagnostic sequencing services and products, and Illumina have agreed to co-market in the Asia Pacific region a new version of Pathogenica's HAI BioDetection kit compatible with Illumina's MiSeq benchtop sequencing system. The combined solution will enable users to identify an expanded panel of bacteria and drug resistance genes present within clinical specimens and mixed cultures or isolates.

More... »

Partners HealthCare, Illumina announce founding members of GeneInsight Network

Monday, January 14, 2013 02:49 PM

Partners HealthCare, a Boston-based integrated health system, and Illumina, a developer, manufacturer and marketer of life science tools and integrated systems, announced the GeneInsight-Illumina Founding Network Members, including the ARUP Laboratories, Mount Sinai Genetic Testing Laboratory, New York Genome Center (NYGC), Partners HealthCare and Illumina.

More... »

Illumina strengthens reproductive health segment with acquisition of Verinata Health

Monday, January 7, 2013 10:26 AM

Illumina, a developer, manufacturer and marketer of life science tools and integrated systems, has signed a definitive agreement to acquire Verinata Health, a provider of non-invasive tests for the early identification of fetal chromosomal abnormalities, for consideration of $350 million, plus up to $100 million in milestone payments through 2015.

More... »

Knome introduces knoSYS100, first plug-and-play human genome interpretation system

Friday, September 28, 2012 12:10 PM

Knome, a Cambridge, Mass.-based provider of human genome interpretation systems and services, has launched its knoSYS100, the first plug-and-play, fully integrated hardware and software system designed to help researchers in medical and academic institutions interpret human whole genomes.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

April 14

Proposal calls for back-to-back trials to measure efficacy and effectiveness prior to FDA approval

Study: Minority populations under-represented in cancer trials, but have higher rates of incidence

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

Make way for mobile health in clinical trials
Despite patient retention, data quality benefits, regulatory hurdles persist

Global clinical trial laboratories decentralize
Regional labs reducing complexity, delivering cost and time savings

Already a subscriber?
Log in to your digital subscription.

Purchase the April issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Strategic alliances hit bumps in the road
Mixed relationship performance driving new approaches

Tapping community hospitals for clinical trial volunteers
New study finds high potential but infrastructure, resources are lacking

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs